Literature DB >> 18242315

Acute leukemias in children with Down syndrome.

Michel C Zwaan1, Dirk Reinhardt, Johann Hitzler, Paresh Vyas.   

Abstract

Children with Down syndrome have an increased risk for developing both acute myeloid as well as lymphoblastic leukemia. These leukemias differ in presenting characteristics and underlying biology when compared with leukemias occurring in non-Down syndrome children. Myeloid leukemia in children with Down syndrome is preceded by a preleukemic clone (transient leukemia or transient myeloproliferative disorder), which may disappear spontaneously, but may also need treatment in case of severe symptoms. Twenty percent of children with transient leukemia subsequently develop myeloid leukemia. This transition offers a unique model to study the stepwise development of leukemia, and of gene dosage effects mediated by aneuploidy.

Entities:  

Mesh:

Year:  2008        PMID: 18242315     DOI: 10.1016/j.pcl.2007.11.001

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  17 in total

1.  Hyperleukocytosis in newborn: a diagnosis of concern.

Authors:  Yusuf Parvez; Aji George Mathew
Journal:  Indian J Hematol Blood Transfus       Date:  2013-07-09       Impact factor: 0.900

2.  Risk of breast cancer in families with cleft lip and palate.

Authors:  Alexander Dietz; Dorthe Almind Pedersen; Rune Jacobsen; George L Wehby; Jeffrey C Murray; Kaare Christensen
Journal:  Ann Epidemiol       Date:  2011-10-28       Impact factor: 3.797

Review 3.  Hematological disorders and leukemia in children with Down syndrome.

Authors:  Annelyse Bruwier; Christophe F Chantrain
Journal:  Eur J Pediatr       Date:  2011-11-24       Impact factor: 3.183

Review 4.  Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians.

Authors:  Judith Frances Margolin
Journal:  Eur J Pediatr       Date:  2011-02-25       Impact factor: 3.183

5.  Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.

Authors:  Trudy D Buitenkamp; Ron A A Mathôt; Valerie de Haas; Rob Pieters; C Michel Zwaan
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

Review 6.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

7.  Treating children with acute lymphoblastic leukemia and Down syndrome: pharmacokinetics provides insight into vincristine therapy.

Authors:  Clinton F Stewart
Journal:  Pediatr Blood Cancer       Date:  2009-01       Impact factor: 3.167

8.  Hospitalizations among people with Down syndrome: a nationwide population-based study in Denmark.

Authors:  Jin Liang Zhu; Henrik Hasle; Adolfo Correa; Diana Schendel; J M Friedman; Jørn Olsen; Sonja A Rasmussen
Journal:  Am J Med Genet A       Date:  2013-02-12       Impact factor: 2.802

9.  Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study.

Authors:  Marjolein Blink; Martin Zimmermann; Christine von Neuhoff; Dirk Reinhardt; Valerie de Haas; Henrik Hasle; Maureen M O'Brien; Batia Stark; Julie Tandonnet; Andrea Pession; Katerina Tousovska; Daniel K L Cheuk; Kazuko Kudo; Takashi Taga; Jeffrey E Rubnitz; Iren Haltrich; Walentyna Balwierz; Rob Pieters; Erik Forestier; Bertil Johansson; Marry M van den Heuvel-Eibrink; C Michel Zwaan
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941

10.  Potential contribution of SIM2 and ETS2 functional polymorphisms in Down syndrome associated malignancies.

Authors:  Arpita Chatterjee; Samikshan Dutta; Sanjit Mukherjee; Nupur Mukherjee; Avirup Dutta; Ashis Mukherjee; Swagata Sinha; Chinmay Kumar Panda; Keya Chaudhuri; Ananda L Roy; Kanchan Mukhopadhyay
Journal:  BMC Med Genet       Date:  2013-01-23       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.